CARE Ratings upgrades Brooks Laboratories to CARE BB
Brooks Laboratories (BROOKS) said CARE Ratings has upgraded its credit rating to CARE BB. The company is valued at about ₹194 crore.
What happened
In a filing with the BSE on 12 November 2026 at 06:14 PM, Brooks Laboratories (BROOKS) said that CARE Ratings has upgraded its credit rating to CARE BB.
From the filing: "The details of the revised credit ratings are as follows : Sr.no Rating For Credit Rating Rating Action 1 Long - term Bank Facilities CARE BB + ;"
Company snapshot
Brooks Laboratories is a micro-cap company, with a market value of about ₹194 crore.
The stock last traded at ₹65.99, against a 52-week range of ₹36.3–₹112.4 (41.3% below the high).
Before this filing the shares had moved −4.3% over the month and +12.8% over three months. Average daily turnover over the last 20 sessions was about ₹0.63 crore.
Promoters held 52.62% at the end of Q2 FY27. Foreign institutions owned 0.04% and domestic institutions 10.50%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q2 FY26 | 23 | 8 | 2.71 |
| Q3 FY26 | 17 | 5.5 | 1.87 |
| Q4 FY26 | 20 | 1.5 | 0.52 |
| Q1 FY27 | 23 | -1.8 | -0.61 |
| Q2 FY27 | 19 | 67.6 | 22.95 |
What history shows
BCEIE has no earlier credit rating filing from this company on record since May 2026.
Market-wide, 1,449 credit rating filings with an impact score of 50 or more saw an average next-day move of +0.1%, with 47% rising.
Past reactions describe what happened before; they are not a forecast.
What to watch
- Whether other agencies take a similar view on the company's credit.
In the news
Recent coverage elsewhere (links open the original publisher):
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.